Topical Therapy for the treatment chronic pain
In 1999 Epitome Pharmaceuticals Ltd. licensed from Dalhousie University (Canada) a patented method for treating neuropathic pain through the topical application of a formulation containing ketamine and amitriptylline. Shortly thereafter we licensed this technology on to EpiCept Corporation of Englewood Cliffs, New Jersey. In 2004, EpiCept made a one-time payment to Epitome for all our remaining rights to the medication.
EpiCept has completed a Phase II trial confirming the medication's efficacy as a safe, non-systemic treatment for chronic pain. EpiCept has created a new formulation and completed safety testing for this cream. They are currently planning the final round of clinical and preclinical tests which will lead to a marketing application.
Early Drug Development in cooperation
with the Pharmaceutical Industry